New Antibody Discovery Benchmark tests whether AI agents can make real scientific decisions
kenbwork · x · 2026-09-04
A new Antibody Discovery Benchmark has been introduced to test whether AI agents can make scientific decisions across the stages of therapeutic antibody discovery.
- 100 evaluations span ten areas drawn from concrete drug programs: target and modality selection, assay design, binder discovery, binding characterization, cellular pharmacology, antibody engineering, and preclinical candidate de-risking.
- The benchmark stresses that antibody discovery is multiparameter and context-dependent: affinity must be weighed alongside specificity, stability, solubility, expression, and biological activity.
- Shared with the framing "Grok for science", pointing to xAI models' potential in scientific workloads.
Related event: LatchBio Releases Antibody Discovery Benchmark for AI Agents(5 posts)→
More from Research
- SimInfinity: open-source robotic simulation benchmark with 10K real-world tasks — joemeno · 2026-10-18
- Auction-based LLM routing paper finds fixed token pricing wastes 10%-71% in costs — _onionesque · 2026-10-18
- Meta paper introduces "agent plasticity": best-performing agent isn't the most efficient learner — rohanpaul_ai · 2026-10-18
- SAE weight editing steers robot behavior at inference time, IIIT Hyderabad paper lands IJCAI Safe Physical AI workshop — ponguru · 2026-10-18
- NTU-led survey reviews nearly 200 papers on affordance learning for embodied AI — jiqizhixin · 2026-10-18
- vega-U: a 14.3M decision engine that cold-attaches to any frozen LLM, 0.811 held-out accuracy — kalyan_kpl · 2026-10-18